Teva Pharmaceutical Industries Ltd: Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva Pharmaceutical and Samsung Bioepis agreed to commercialize two FDA-approved biosimilars in the U.S. Teva will obtain rights to ETICOVO upon close and infliximab-abda in Q3 2027. The deal expands Teva's biosimilars portfolio as part of its Pivot to Growth strategy. Samsung Bioepis will retain regulatory and manufacturing responsibilities. Financial terms include an upfront payment and potential milestone payments.
How this was made
The 30-second read
Why it matters
The agreement provides Teva with two additional TNF‑inhibitor biosimilars, potentially increasing its market share in chronic inflammatory therapies.
Market read
The deal is a fresh, material partnership that could boost Teva's revenue outlook and influence the biosimilars market.
What to watch
Regulatory approval timelines and manufacturing capacity constraints could delay revenue realization.
Background
Teva is pursuing its "Pivot to Growth" strategy, focusing on expanding its generics and biosimilars portfolio.
Ticker impact
Teva announced a new license and commercialization agreement with Samsung Bioepis for two FDA‑approved biosimilars, adding U.S. rights to etanercept‑ykro now and infliximab‑abda in Q3 2027.
potential upside as investors price in expanded biosimilar pipeline and future sales
New commercial rights are material to Teva's growth strategy; no prior announcement existed.
Market effects
strengthens the U.S. biosimilars segment and may pressure competitors in the immunology space.
adds to Teva's U.S. market exposure while highlighting South Korean biotech partnerships.
shows growing cross‑border collaborations in biologics, a trend watched by global pharma investors.
Counterpoint
If the biosimilars face pricing pressure or reimbursement hurdles, the deal may not translate into earnings uplift.
Key entities
- CompanyTeva Pharmaceutical Industries Ltd.
US‑listed pharmaceutical company acquiring U.S. commercialization rights.
- CompanySamsung Bioepis Co., Ltd.
South Korean biotech partner supplying the biosimilars.
